While clinically relevant direct Ras-like (Ral) inhibitors are lacking, dinaciclib, a cyclin-dependent kinase inhibitor, has been shown to inhibit CDK5-mediated activation of Ral signaling.33, 35 We evaluated the effects of dinaciclib on RALB signaling in AML cell lines. This evidence concerns the gene RALA and acute myeloid leukemia.